BMS to boost CAR T cell therapy production with Cellares deal
The deal, valued at up to $380m, includes upfront and milestone payments. Under the terms of the agreement, Cellares will streamline, automate, and transfer technology for selected BMS
Biotechnology company PRISM BioLab has signed a target exclusive research and licensing agreement with Japan headquartered company ONO Pharmaceutical for jointly creating a development candidate for the latter’s oncology target.
This partnership follows the US Food and Drug Administration’s approval of ADSTILADRIN in December 2022 for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)